Status:
COMPLETED
Effect of Kombucha Consumption on the Microbiome in Healthy Subjects
Lead Sponsor:
University of California, San Diego
Collaborating Sponsors:
GT's Living Foods
Conditions:
Health Behavior
Eligibility:
All Genders
21-55 years
Phase:
NA
Brief Summary
This proposed pilot study will assess the ability of consumption of two servings of kombucha daily to decrease inflammation, alter the gut microbiome composition, and improve intestinal wellbeing in a...
Detailed Description
An altered intestinal gut microbiota, i.e. dysbiosis, has been associated with the development of intestinal disease including inflammatory bowel disease and metabolic diseases such as obesity, type 2...
Eligibility Criteria
Inclusion
- Typically consume low fiber/polyphenol diet (beige diet)
- BMI within 25-29.9 kg/m2
Exclusion
- Eating a high fiber/polyphenol diet or taking any medication or dietary supplement, which interfere with the absorption of polyphenols
- History of gastrointestinal surgery, diabetes mellitus on medications, or other serious medical condition, such as chronic hepatic or renal disease, bleeding disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as systolic BP \>160mmHg, diastolic BP \> 95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, laxative abuse, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history or routine physical examination
- Is unable or unwilling to comply with the study protocol
- Using prebiotics, probiotics, yogurt, and/or any fiber supplements regularly
- Taking antibiotics or laxatives within the past 3 months
- Allergy or sensitivity to kombucha
- In the opinion of the study investigator, any subject who demonstrate a risk of non-compliance with study procedure, or one who cannot read, understand, or complete study
Key Trial Info
Start Date :
March 3 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 25 2024
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT06484504
Start Date
March 3 2022
End Date
April 25 2024
Last Update
July 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UC San Diego ACTRI
La Jolla, California, United States, 92037